CRISPR 2.0 2020

Memo

CRISPR is one of the most powerful discoveries of the last decade. In a remarkably short space of time, 'classic' CRISPR-Cas9 has established itself as a reliable tool in the genomics toolbox, which leads to the question: what's next? CRISPR 2.0 is the industry-leading meeting dedicated to answering this question by showcasing only the latest and greatest innovations in CRISPR technology, from the potential of prime editing through to epigenome editing to treat chronic pain. Don't get left behind. Join leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic and academic organizations breaking new ground in establishing novel CRISPR tools. Join us to usher in the next generation of safe, targeted and effective genome editing. Date and Time: On Tuesday November 17, 2020 at 9:00 am ends Thursday November 19, 2020 at 6:00 pm Venue details: Embassy Suites by Hilton Boston Waltham, 550 Winter Street, Waltham, Massachusetts, 02451, United States Prices:Conference + 2 Workshops OR Discussion Day (Industry): USD 3397.00,Conference + 1 Workshop (Industry): USD 2948.00,Conference Only (Industry): USD 2499.00,Discussion Day Only (Industry): USD 1098.00,Workshop Only (industry): USD 549.00,Conference + 2 Workshops OR Discussion Day (Vendor Pricing): USD 4897.00,Conference + 1 Workshop (Vendor Pricing): USD 4198.00,Conference Only (Vendor Pricing): USD 3499.00 Speakers: Amr Abdeen, Postdoctoral Associate, University of Wisconsin- Madison, Omar Abudayyeh, McGovern Fellow, Harvard University, Alejandro Amador, Head of High Throughput Biology, Functional Genomics GlaxoSmithKline, Andrew Anzalone, Postdoctoral Fellow Liu Group, Broad Institute, Luis Barrera, Head of Computational Sciences, Beam Therapeutics, Carsten Charlesworth, Graduate, Stanford University, Delai Chen Associate Director, Nanoparticle Formulation, Beam Therapeutics, Paul Diehl, Chief Operating Officer, Cellecta, Rafi Emmanuel, Research Director, Emendo Biotherapeutics, Jonathan Gootenberg, McGovern Fellow, Harvard University, Julian Grunewald, Research Fellow Joung Lab, Massachusetts General, Killian Hanlon, Research Fellow, Harvard University, Ben Kleinstiver, Principal Investigator, Massachusetts General, Sanne Klompe, Graduate Sternerg Lab, Columbia University, Kunwoo Lee, Chief Executive Officer and Co-Founder, GenEdit, Blair Madison Senior Director, Genetic Engineering, Poseida Therapeutics, Ana Moreno, Founder and Chief Executive Officer, Navega Therapeutics, Ana Moreno, Founder and Chief Executive Officer, Navega Therapeutics, Kiran Musunuru, Principal Investigator, University of Pennsylvania, Kalina Paunovska, Postdoctoral Fellow Dahlman Lab, Georgia Tech, Karl Petri, Research Fellow Joung Lab, Massachusetts General, Sicco Popma Founder, Chief Executive Officer and President, IO Biosciences, Satinder Rawat, Senior Licensing Officer, University of Massachusetts, David Schaffer, Co-Founder, 4D Molecular Therapeutics, Brett Staahl, Founder and Head of Applied Technologies, Scribe Therapeutics, Marija Tadin- Strapps, Vice President, Exploratory Biology, SQZ Biotechnologies, Fyodor Urnov, Scientific Director, Innovative Genomics Institute, Rui Wang, Principal Research Scientist, Abbvie, Renee Wegrzyn, Program Manager, DARPA, Carlo Zambonelli, Associate Director, Beam Therapeutics, Kate Zhang, Vice President, Biological Development, Editas Medicine, Lihua Julie Zhu, Professor and Head of Bioinformatics Core, University of Massachusetts, Speaker to be Confirmed, Aldevron